Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7873570 | 0.80 | NISCH (0.34) | AXLNUDT1 | |
| SCHEMBL1938638 | 0.71 | CYP1A2 (0.31) | CYP1A2SMN1; SMN2 | |
| SCHEMBL29967313 | 0.71 | CYP1A2 (0.31) | CYP1A2SMN1; SMN2 | |
| SCHEMBL30051018 | 0.70 | NOS2 (0.39) | NOS2 | |
| SCHEMBL7835774 | 0.70 | — | — | |
| SCHEMBL3541131 | 0.68 | NOS2 (0.38) | NOS2 | |
| Bromide SCHEMBL7993026 | 0.68 | NOS2 (0.38) | NOS2 | |
| SCHEMBL388290 | 0.67 | — | — | |
| SCHEMBL14989970 | 0.67 | AXL (0.32) | AXLNUDT1CYP1A2SMN1; SMN2 | |
| SCHEMBL870400 | 0.67 | CYP1A2 (0.31) | CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | claimed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | claimed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | claimed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | claimed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | claimed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | claimed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | claimed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| JP-4230684-A | — | — | None | — | — | JP | disclosed |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INST NAT SANTE RECH MED (FR) | 2025-11-27 | — | — | US | disclosed |
| WO-2002000593-A2 | COMPOUNDS USEFUL FOR THE PREPARATION OF MEDICAMENTS WITH PHOSPHODIESTERASE IV INHIBITORY ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-01-03 | — | — | WO | disclosed |
| JP-H04230684-A | 4-SUBSTITUTED DIHYDROPYRIDO(4,3-D)PYRIMIDINE AS ANALGESIC AND LOCAL ANTI-INFLAMMATORY DRUG FOR TREATING SKIN DISEASE | HOECHST ROUSSEL PHARMACEUT INC | 1992-08-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NOS2 1676/4885AXL 3616/4885NUDT1 15/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NOS2 1676/4885AXL 3616/4885NUDT1 15/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NOS2 1345/4885AXL 2930/4885NUDT1 9/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NOS2 1676/4885AXL 3616/4885NUDT1 15/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NOS2 1345/4885AXL 2930/4885NUDT1 9/4885 |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | SARS1, CCR5, INTS6 | NOS2 3868/4885AXL 1473/4885NUDT1 1242/4885 |
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | NOS2 3699/4885AXL 3972/4885NUDT1 539/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NOS2 1345/4885AXL 2930/4885NUDT1 9/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | NOS2 3699/4885AXL 3972/4885NUDT1 539/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NOS2 1345/4885AXL 2930/4885NUDT1 9/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NOS2 1676/4885AXL 3616/4885NUDT1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.